Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study-Reference-Cited by-同舟云学术

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Published:2011-04 Issue:4 Volume:64 Page:671-681
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Strober Bruce E.,Poulin Yves,Kerdel Francisco A.,Langley Richard G.,Gu Yihua,Gupta Shiraz R.,Okun Martin M.,Papp Kim A.

Publisher

Elsevier BV

Subject

Dermatology

Reference29 articles.

1. Psoriasis causes as much disability as other major medical diseases;Rapp;J Am Acad Dermatol,1999

2. Psoriatic arthritis: epidemiology, clinical features, course;Gladman;outcome. Ann Rheum Dis,2005

3. Initial experience with routine administration of etanercept in psoriasis;de Groot;Br J Dermatol,2006

4. Molecular differences in anticytokine therapies;Calabrese;Clin Exp Rheumatol,2003

5. Ko H-S. Clinical trial design in psoriasis. Oral presentation at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee; March 20, 1998; Bethesda, MD.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review;Annals of Medicine;2023-04-04

2. Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases;Biology;2022-05-25

3. TNF-Alpha Class of Biologic Agents in Psoriatic Disease;Updates in Clinical Dermatology;2022

4. Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation;Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.;2021-10-01

5. Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy;Expert Opinion on Biological Therapy;2021-07-18